

**Acknowledgment and Consent for Disclosure of
18 U.S.C. §208
Particular Matter Waiver**

David Shaffer, M.D.

Committee: Psychopharmacologic Drugs Advisory Committee

Meeting Date: February 6, 2008

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to discussions of new drug application (NDA) 22-173 Zyprexa Adhera (olanzapine pamoate depot) long acting intramuscular (IM) injection 210mg, 300mg, and 405 mg per/vial, sponsored by Eli Lilly & Company, for treatment of schizophrenia, I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

Type of Interest	Nature	Magnitude
Employer's study of a competing product for unrelated indication	Competitor	Less than \$100,001 per year
Employer's study of a competing product	Competitor	Less than \$100,001 per year
Employer is negotiating a grant for a competing product for unrelated indication	Competitor	Less than \$100,001 per year

I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued by reading the statement into the record at the time of the meeting. I understand that without public disclosure of these interests the waiver is not valid.

_____/S/
Signature of SGE

_____/1/15/08
Date